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Background: Src-associated in mitosis (Sam68; 68 kDa) has been implicated in the oncogenesis and progression of
several human cancers. The aim of this study was to investigate the clinicopathologic significance of Sam68
expression and its subcellular localization in colorectal cancer (CRC).
Methods: Sam68 expression was examined in CRC cell lines, nine matched CRC tissues and adjacent noncancerous
tissues using reverse transcription (RT)-PCR, quantitative RT-PCR and Western blotting. Sam68 protein expression
and localization were determined in 224 paraffin-embedded archived CRC samples using immunohistochemistry.
Statistical analyses were applied to evaluate the clinicopathologic significance.
Results: Sam68 was upregulated in CRC cell lines and CRC, as compared with normal tissues; high Sam68
expression was detected in 120/224 (53.6%) of the CRC tissues. High Sam68 expression correlated significantly with
poor differentiation (P = 0.033), advanced T stage (P < 0.001), N stage (P = 0.023) and distant metastasis (P = 0.033).
Sam68 nuclear localization correlated significantly with poor differentiation (P = 0.002) and T stage (P =0.021).
Patients with high Sam68 expression or Sam68 nuclear localization had poorer overall survival than patients with
low Sam68 expression or Sam68 cytoplasmic localization. Patients with high Sam68 expression had a higher risk of
recurrence than those with low Sam68 expression.
Conclusions: Overexpression of Sam68 correlated highly with cancer progression and poor differentiation in CRC.
High Sam68 expression and Sam68 nuclear localization were associated with poorer overall survival.
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Colorectal cancer (CRC) is one of the most prevalent
malignancies worldwide. Although advances have been
made in diagnostic and therapeutic techniques, the
prognosis of CRC patients with distant metastases still
remains poor [1]. Thus, characterization of the molecu-
lar mechanism that involves in progression and metasta-
sis of CRC could help to identify specific biomarkers* Correspondence: dyq@fimmu.com; lb.song1@gmail.com
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Src-associated in mitosis, 68 kDa (Sam68) belongs to
the signal transduction and activation of RNA (STAR)
family of K homology (KH) domain-containing RNA
binding proteins [2] and is originally identified as a sub-
strate for Src kinase phosphorylation during mitosis [3,4].
Sam68 is ubiquitously expressed and plays important roles
in signaling transduction, gene transcription, and alterna-
tive splicing [2,5]. Sam68 has been suggested to act as an
adaptor in signal transduction by binding to SH3- and
SH2-containing proteins, through its proline-rich regions
[6]. Additionally, Sam68 can interact with signaling pro-
teins, such as Src, Grb2, Grap, SHP-1, PLCγ1/Fyn, BRK
and PI3K, and has been implicated in T-cell receptor and. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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pathways [7-11]. Moreover, Sam68 is usually a nuclear
protein and plays a major role in the regulation of RNA
metabolism, including mRNA transcription, alternative
splicing and nuclear export [12-17]. The alternative spli-
cing of multiple genes regulated by Sam68, including
those involved in oncogenesis, such as CD44, Bcl-xl, Sgce,
SMN2, SF2/ASF and Cyclin D1 [6,14-19].
The above mentioned biological functions of Sam68
closely linked this protein to oncogenic properties. First,
Sam68 is involved in promotion of cell cycle progression,
cell proliferation, transformation, tumorigenesis and me-
tastasis in different cellular context [20-25]. Second, a
series of published articles in the recent decade have dem-
onstrated that Sam68 participates in transcriptional and
post-transcriptional regulation of gene expressions that
are relevant to human cancer [14,15,17,18,20,26]. How-
ever, deregulation of Sam68 in human cancer tissues has
only been observed in limited cancer types, including
prostate cancer, renal cell carcinoma, breast and cervical
cancer [23,24,26-28]. Whether the deregulation of Sam68
is a prevalent event in human cancer needs further inves-
tigation. To explore the deregulation of Sam68 in human
colorectal cancer, we investigated the expression patterns
of Sam68 in human CRC tissues, and the correlation be-
tween Sam68 expression levels and the clinicopathologic
features of CRC. Our current study indicates that the ex-
pression and localization of Sam68 may act as independ-
ent biomarkers of prognosis in CRC, suggesting that




Colorectal cancer cell lines including LS174t, Colo205,
SW480, HT29, HCT116 and SW620 cells were cultured in
RPMI 1640 (Invitrogen, Carlsbad, CA, USA) supplemented
with 10% fetal bovine serum, 100 μg/μL streptomycin and
100 μg/μL penicillin in a humidified incubator containing
5% CO2 at 37°C.
Patients and tissue specimens
For the use of clinical materials for research purposes,
prior patients' consents and approval were obtained from
the Sun Yat-sen University and Cancer Center Institu-
tional Board. All samples were collected and analyzed with
prior written informed consents from the patients. A total
of 224 paraffin-embedded colorectal cancer samples,
which were histopathologically and clinically diagnosed at
the Sun Yat-sen University Cancer Center between the
year 2000 to 2003, were examined. All of the patients had
received chemotherapy after surgery. Prior patient consent
and approval were obtained from the Institutional Re-
search Ethics Committee.The clinicopathological features of the patients are
summarized in Additional file 1: Table S1. The final
study population included 97 female and 127 male pa-
tients (age range, 23–82 years). Follow-up was recorded
from the date of surgery until death. Patients who died
of cancer (or other causes) were classified as dead. The
median follow-up time for all patients was 58.47 months.
43 corresponding metastatic lymph nodes were also
obtained from the above mentioned patients. Four pairs
of CRC biopsies and the matched adjacent non-
cancerous colon tissues were obtained from each patient
during surgery, and immediately frozen and maintained
in liquid nitrogen until further use.
RNA extraction, reverse transcription-polymerase chain
reaction and quantitative Real-time polymerase chain
reaction
Total RNA was extracted from the cultured cells and
surgical tissues using TRIzol reagent (Invitrogen)
according to the manufacturer's instructions. Reverse
transcription polymerase chain reaction (RT-PCR) and
quantitative real-time polymerase chain reaction (Q-
PCR) analysis of Sam68 expression were performed as
previously described [29], using previously published
primers and probes [28]. Sam68 expression was analyzed
using the 2-ΔΔCt method as described by Livak et al. [30]
and normalized to the geometric mean expression level
of the housekeeping gene glyceraldehyde-3-phosphate
dehydrogenase (GAPDH). The relative change in Sam68
expression was calculated by pair-wise comparison of
the normalized Sam68 expression level in the tumor
samples with the adjacent non-cancerous tissue samples
from the same patient.
Western blotting
Tissue and cell lysates were prepared using SDS lysis
buffer and the protein concentration was determined
using the Bradford assay (Bio-Rad Laboratories,
Hercules, CA, USA). Equal amounts of protein were
separated by electrophoresis on a 10.5% sodium dodecyl
sulfate polyacrylamide gel and electrotransferred from
the gel to a nitrocellulose membrane. After blocking
with 5% milk solution in Tris-buffered saline with Tween
(TBST) for 1 hour, the membrane was incubated with
primary antibody against rabbit antibody Sam68 (sc-333,
dilution, 1:500; Santa Cruz Biotechnology, CA, USA)
and rabbit anti-α-Tubulin (1:1000, Sigma, Saint Louis,
MI, USA) primary antibodies. After washing with TBS-T,
the membrane was incubated with secondary antibody
against rabbit immunoglobulin G or mouse immuno-
globulin G; then, it was examined with the enhanced
chemiluminescence detection system (Amersham Biosci-
ences Europe, Freiberg, Germany) according to the man-
ufacturer’s instructions.
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Paraffin sections were deparaffinized with xylene and
rehydrated, then submerged into EDTA antigenic re-
trieval buffer and microwaved for antigenic retrieval.
The sections were then treated with 3% hydrogen per-
oxide in methanol to quench the endogenous peroxid-
ase activity, followed by incubation with 1% BSA to
block the non-specific binding. The sections were incu-
bated with rabbit anti-Sam68 (sc-333, dilution, 1:500;
Santa Cruz Biotechnology, CA, USA) overnight at 4°C.
As negative controls, rabbit anti-Sam68 antibody was
replaced with normal goat serum, or the rabbit anti-
Sam68 antibody was blocked by co-incubation with a
recombinant Sam68 polypeptide at 4°C overnight prior
to the immunohistochemical staining. The staining
intensity was scored on a scale of 0 to 3 as 0 (no stain-
ing), 1 (weak staining ~ light yellow), 2 (moderate stain-
ing ~ yellowish brown) or 3 (strong staining ~ brown).
Tumors with a staining intensity ≥ 2 in which at least
50% of the malignant cells were Sam68-positive were
classified as high expression; tumors with a staining
intensity < 2 or in which less than 50% of the malignant
cell were Sam68-positive were classified as low expression.
Statistical analysis
All statistical analyses were carried out using SPSS
10.0 (Chicago, IL, USA). The significance of the differ-
ences between the normal and tumor tissue Q-PCR re-
sults were assessed using the Student’s two-tailed t-test.
The association between Sam68 expression and clinico-
pathological variables were assessed using the Mann–
Whitney U test. Survival curves were plotted using
the Kaplan-Meier method. The Cox proportional haz-
ards regression model was used for univariate and
multivariate analysis. Two-tailed P values < 0.05 were
considered significant.Figure 1 Analysis of Sam68 protein and mRNA expression in colorect
of Sam68 protein expression in CRC cell lines (LS174t, Colo205, SW480, HT2
N2) by Western blotting. (B) Analysis of Sam68 mRNA expression by RT-PC
intestine tissues by Q-PCR, the average ratio of Sam68 expression normaliz
parallel experiments.Results
Expression of Sam68 in colorectal cancer cell lines
We examined the expression of Sam68 using Western
blotting in seven human colon cancer cell lines and two
cases of normal intestine tissues. The results displayed
that Sam68 protein expression level was much higher
in CRC cell lines than that in normal intestine tissues
(Figure 1A). We next measured the expression of Sam68
mRNA in the CRC cell lines using RT-PCR (Figure 1B)
and (Figure 1C). In agreement with the protein expres-
sion levels, the Sam68 mRNA expression level was
much higher in CRC cell lines than that in normal in-
testine tissues.
Sam68 is upregulated in primary human CRC lesions
Western blotting and RT-PCR analyses were performed
to determine the expression of Sam68 in nine paired pri-
mary CRC tissues and the matched adjacent non-
cancerous tissues. Sam68 was significantly upregulated
at both the protein (Figure 2A) and mRNA levels
(Figure 2B) in all nine of the CRC tissues tested, com-
pared to the matched adjacent normal tissues from the
same patient. Q-PCR results confirmed that Sam68
mRNA was upregulated in the tumor samples by up to
18.3-fold (Sam68 tumor/normal [T/N] ratio; Figure 2C;
P < 0.01, Student’s t-test).
In agreement with the Western blotting results, immu-
nohistochemical analysis confirmed that Sam68 was
overexpressed in all nine of the CRC tissues tested,
compared with the paired adjacent normal tissues
(Figure 2D). Taken together, these results indicated that
Sam68 is upregulated in CRC lesions at both transcrip-
tional and translational levels.
We further performed immunohistochemical analysis
to determine the expression patterns of Sam68 in 224
paraffin-embedded CRC tissues and 43 lymph nodeal cancer (CRC) cell lines and normal intestine tissues. (A) Analysis
9, HCT116, SW620) and two cases of normal intestine tissues (N1 and
R. (C) Analysis of Sam68 mRNA expression in CRC cell lines and normal
ed to GAPDH is shown; values are the mean ± SD of three
Figure 2 Sam68 is upregulated in primary colorectal cancer (CRC) tissues compared with the adjacent normal tissues. (A, B) Analysis of
Sam68 mRNA expression in primary CRC tissues (T) and the paired adjacent normal tissues (N) by RT-PCR (A) and Q-PCR (B). GAPDH was used as
loading control. (C, D) Analysis of Sam68 protein expression in primary CRC tissues and the paired adjacent normal tissues by Western blotting
(C) and immunohistochemistry (D).
Liao et al. BMC Gastroenterology 2013, 13:126 Page 4 of 9
http://www.biomedcentral.com/1471-230X/13/126metastatic tissues. Negative to moderate Sam68 staining
was detected in the adjacent normal tissues (Figure 3A-
D); however, positive Sam68 staining was detected in
206 of the 224 (92%) tumor tissues. The tumors could
be divided into a low Sam68 expressing group (104
cases) and a high Sam68 expressing group (120 cases,
Additional file 1: Table S1). Additionally, two main pat-
terns of Sam68 protein expression were observed in the
tumors: cytoplasmic localization (Figure 3E-F) and nu-
clear localization (Figure 3G-J). As shown in Additional
file 1: Table S1, 61.6% (138/224) of the tumor samples
displayed nuclear staining and 38.4% (86/224) displayed
cytoplasmic staining. Moreover, positive expression of
Sam68 was detected in 81.4% (35/43) of the lymph node
metastases (Figure 4) and 65.1% (28/43) of lymph node
metastases were classified as high Sam68 expressing.
Correlations between increased expression of Sam68 and
clinical aggressiveness in CRC
Statistic analyses were performed to evaluate the expres-
sion patterns of Sam68 and the clinicopathological fea-
tures of CRC. As shown in Table 1, the high Sam68expression level was strongly correlated with poor tumor
differentiation (P = 0.033), advanced T stage (P < 0.001),
N stage (P = 0.023), and distant metastasis (P = 0.033) in
this cohort of 224 cases of CRC. In addition, high ex-
pression level of Sam68 was significantly associated with
the nuclear localization of Sam68 (P = 0.012). Moreover,
Nuclear localization of Sam68 correlated significantly
with tumor differentiation (P = 0.002) and advanced
T stage (P = 0.021). These observations suggest that in-
creased expression of Sam68 or nuclear localization of
Sam68 was closely associated with aggressive phenotypes
of CRC.
Sam68 is associated with poor prognosis in CRC patients
In univariate Cox regression analysis, tumor differenti-
ation, T stage, N stage and distant metastasis were sig-
nificant prognostic factors in this cohort of CRC
patients (Additional file 2: Table S2; P < 0.001). Kaplan-
Meier survival analysis demonstrated that patients with
low levels of Sam68 expression had significantly longer
median survival than patients with low Sam68 expres-
sion (Figure 5A, upper panel; 71 vs. 51 months; P =
Figure 3 Representative images of Sam68
immunohistochemical analysis in colorectal cancer (CRC)
tissues. (A – D) Negative (A, 100X; B, 400X) or moderate (C, 100X;
D, 400X) Sam68 staining was detected in the adjacent non-
cancerous tissues. (E – H) Cytoplasmic Sam68 staining (E, 100X; F,
400X) or nuclear Sam68 staining (G, 100X; H, 400X) was observed in
primary CRC tissues. (I – J) Sam68 was upregulated in CRC
compared to the paired adjacent non-cancerous tissues (I, 100X; J,
400X).
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with low Sam68 expression was 70% (95% confidence
interval, 0.609-0.779), compared to 54% (95% confidence
interval, 0.448-0.635) for patients with high Sam68
expression.
Next, we analyzed the relationship between the ex-
pression of Sam68 in metastatic lymph nodes and
survival. Kaplan-Meier analysis indicated that the ex-
pression level of Sam68 in the metastatic lymph nodeshad a significant impact on survival (Figure 5B; P =0.029,
log-rank test), as the median overall survival time of pa-
tients expressing low levels of Sam68 in the metastatic
lymph nodes was significantly longer than patients express-
ing high levels of Sam68 in the metastatic lymph nodes
(log-rank test, P = 0.029).
We also analyzed the prognostic value of the subcellu-
lar localization of Sam68 in CRC. Spearman’s rank cor-
relation revealed that nuclear localization of Sam68 in
CRC tumors correlated significantly with poorer survival
(Spearman Rho −0.232, P = 0.001). Additionally, Kaplan-
Meier survival analysis confirmed that the median sur-
vival time for patients with Sam68 nuclear localization
was significantly shorter than patients with Sam68 cyto-
plasmic localization (Figure 5C; 54 vs. 73 months, P =
0.024, log-rank test). The 5-year survival rate for patients
with Sam68 cytoplasmic localization was 70% (95% con-
fidence interval, 0.609-0.779), compared to 54% (95%
confidence interval, 0.448-0.635) for patients with
Sam68 nuclear localization. The Sam68 expression level,
subcellular localization of Sam68, pathological stage and
N stage were identified as independent prognostic fac-
tors for overall survival in CRC in multivariate survival
analysis (Additional file 3: Table S3 and Additional file 4:
Table S4).
Furthermore, in the subgroups of CRC patients with-
out distant metastasis (M0) or with well/moderately dif-
ferentiated tumors, both the Sam68 expression level
(Figure 6A and C) and subcellular localization of Sam68
(Figure 6E and G) correlated significantly with overall
survival. However, no such correlations were observed in
the subgroup of patients with distant metastasis or
poorly differentiated tumors (Figure 6B,D,F and H).
Discussion
Sam68 is a substrate of the oncogenic Src kinase, which
is often activated in human cancers [4]. Previous re-
searches suggested that two opposing functions of
Sam68 were reported in different cellular contexts. On
one hand, a few studies indicated that Sam68 acted as a
tumor suppressor. For example, Sam68 deficiency
resulted in neoplastic transformation of murine NIH3T3
fibroblasts. Reduction of Sam68 was associated with
anchorage-independent growth, defective contact inhib-
ition, and the ability to form metastatic tumors in nude
mice [31], while overexpression of Sam68 in NIH-3 T3
fibroblasts led to both cell cycle arrest and apoptosis
[21]. On the other hand, a large proportion of recent re-
ports demonstrated that Sam68 played an oncogenic
role. Sam68 knockdown in polyoma middle T-antigen
(PyMT) oncogene transformed cell lines delayed tumori-
genesis and metastasis formation in nude mice [25].
Busà R and colleagues have demonstrated that Sam68
was upregulated in prostate cancer at both protein and
Figure 4 Immunohistochemical analysis of Sam68 expression in metastatic lymph node tissues from colorectal cancer (CRC) patients.
Negative, moderate or strong Sam68 staining was observed in CRC metastatic lymph node tissues.
Table 1 Correlation between clinicopathologic features and Sam68 expression levels and localization





valuesLow High Nuclear Cytoplasm
Age
≤ mean(56) 50 56 0.833 66 40 0.848
> mean (56) 54 64 72 46
Gender
Male 61 66 0.583 76 51 0.535
Female 43 54 62 35
Histology
Columnar adenocarcinoma 79 102 110 71 0.733
Mucinous adenocarcinoma 14 11 0.083 19 6
Others 11 7 9 9
Differentiation
Well and moderate 87 86 0.033 97 76 0.002
Poor and undifferentiated 17 34 41 10
T stage
1 ~ 2 27 13 18 22 0.021
3 58 64 <0.001 77 45
4 19 43 43 19
N stage
0 68 59 0.023 72 55 0.072
1 27 48 50 25
2 9 13 16 6
Distant metastasis
0 (no) 78 74 0.033 89 63 0.173
1 (yes) 26 46 49 23
Sam68 localization
Nuclear 55 83 0.012
Cytoplasm 49 37
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Figure 5 Influence of Sam68 expression on overall survival in colorectal cancer (CRC). (A) Kaplan–Meier curves showing that patients with
high Sam68 expression had poorer overall survival than patients with low Sam68 expression; analysis of 224 primary CRC tissues (P = 0.003).
(B) Kaplan–Meier curves showing that patients with high Sam68 expression in metastatic lymph node tissues had poorer overall survival than
patients with low Sam68; analysis of 43 metastatic lymph node tissues (P = 0.029). (C) Kaplan–Meier curves showing that patients with nuclear
Sam68 expression had poorer overall survival than patients with cytoplasmic Sam68 expression; analysis of 224 primary CRC tissues (P = 0.005).
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in prostate cancer cells delayed cell cycle progression
and reduced the proliferation rate [23]. Sam68 is also
upregulated and its upregulation is correlated with shorter
survival rates in breast cancer, cervical cancer, renal cell
carcinoma [24,27,28]. The present study demonstrated that
Sam68 was elevated in CRC tissues and the high Sam68
expression level was significantly correlated with the char-
acteristics of aggressive CRC (including poor differentiation
of tumors, advanced T stage, lymph node involvement andFigure 6 Overall survival curves for colorectal cancer (CRC) patients s
classification and tumor differentiation. In the M0 classification (A) and
Sam68 expression had significantly better overall survival than patients with
poorly differentiated tumor subgroups (D), the overall survival of patients w
the M0 classification (E) and moderately differentiated tumor subgroups (G
overall survival (P = 0.027 and P = 0.024, respectively) than patients with Sam
differentiated subgroups (H), the overall survival of patients with Sam68 cydistant metastasis). Additionally, high Sam68 expression
level was a significant predictor of poor prognosis in CRC
patients. Thus, our results raised the evidence that sug-
gested that Sam68 might promote development and pro-
gression of human CRC, supporting the pro-oncogene role
of Sam68 in human cancer.
Sam68 is a ubiquitously expressed protein and resides
in both cytoplasm and nuclei [2]. Posttranslational modi-
fications of Sam68, such as phosphorylation and methy-
lation, can affect its subcellular localization, interactiontratified by the Sam68 expression level, according to M
moderately differentiated tumor subgroups (C), patients with low
high Sam68 expression (P = 0.01). In the M1 classification (B) and
ith high and low Sam68 expression was not significantly different. In
), patients with Sam68 cytoplasmic localization had significantly better
68 nuclear localization. In the M1 classification (F) and poorly
toplasmic and nuclear localization was not significantly different.
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[2,15,32-35]. In most cells, Sam68 predominantly resided
within the nucleus and is involved in gene transcription,
alternative splicing, and nuclear export [12-19]. Sam68
has been observed to exist in dynamic nuclear foci termed
Sam68 nuclear bodies (SNBs), also called stress nuclear
bodies [12,36]. Genes regulated by Sam68 include CD44,
Bcl-xl, Sgce, SMN2, SF2/ASF, Cyclin D1, and so on, which
are all involved in oncogenesis [6,14-19]. In the present
study, Sam68 was found to localize to both the nuclei and
cytoplasm of cancer cells. It is particularly noteworthy that
the subgroup of patients with advanced clinical stage CRC
often exhibited nuclear localization of Sam68, while CRC
patients with well differentiated or early stage tumors
often displayed cytoplasmic Sam68 staining. In addition,
patients with cytoplasmic Sam68 localization had a better
clinical outcome than patients with Sam68 nuclear
localization. These researches suggested that nuclear
Sam68 might play a dominant role in oncogenesis of CRC.
However, distinguished from our results, cytoplasmic
localization of Sam68 was significantly correlated with
cancer progression and poor prognosis in human renal
cell carcinoma and breast cancer [24,27]. It could be due
to the functions of Sam68 in multiple signaling pathways,
since it can be expressed in both the cytoplasm and nu-
cleus. In the cytoplasm, Sam68 interacts with signaling
molecules such as Src, Grb2, Grap [7-11] and stimulates
oncogenic pathways, including the epidermal growth
factor pathway, ERK and AKT pathways [37,38]. In
renal cell carcinoma and breast cancer, the oncogenic
role of Sam68 was closely associated with its activation
of Akt/GSK-3β pathway [24,27]. Taken together, these
researches suggested that cytoplasmic and nuclear
localization of Sam68 might contribute to neoplastic
transformation or tumor progression through different
molecular mechanisms in different cancer types or cel-
lular contexts.
This study provides the first evidence to indicate that
both high expression level and nuclear localization of
Sam68 correlate significantly with invasiveness and ag-
gressiveness characteristics in CRC, and poorer survival
of CRC patients. Taken together, this study suggests that
Sam68 may represent a novel indicator of progression
and prognosis in CRC.
Conclusions
In conclusion, Sam68 was upregulated in primary human
CRC, and high Sam68 expression levels in CRC were asso-
ciated with the clinical features of aggressive disease and
poorer patient prognosis. Nuclear localization of Sam68 in
CRC was identified as an independent predictor of poor
prognosis. However, further characterization of the mech-
anisms by which Sam68 is involved in the transformation
and progression of human CRC is required.Additional files
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